Status message

We are currently rebuilding the search index. Some search results may be inaccurate or incomplete.

SEARCH RESULTS

8690 RESULTS

Sort By:

RG7129

THERAPEUTICS Roche Products (Ireland) Limited RO5508887 BACE1 Inhibitor Small Molecule APP and Amyloid-Related In October 2013, Roche terminated development of this compound. No reason was given for the discontinuation. Three Phase 1 trials have been completed. In Jan

AZD3293

THERAPEUTICS AstraZeneca BACE1 inhibitor Small Molecule APP and Amyloid-Related In December 2012, AstraZeneca started a Phase 1 study that evaluated the safety and pharmacological effects of single doses of oral AZD3293 in 72 healthy volunteers. Doses ranged from 1–1,

E2609

THERAPEUTICS Eisai Co., Ltd. BACE1 inhibitor Small Molecule APP and Amyloid-Related Four Phase 1 trials were completed. They evaluated the safety and pharmacology of E2609 in a total of 141 healthy volunteers. One trial focused on bioavailability with food in particul

Assistant Professor- Cognitive/Behavioral Neurologist

JOB 2013-09-17 Employer Vanderbilt University Contact Interested candidates should submit a C.V., a brief statement summarizing clinical interests and research objectives, and three letters of recommendation to:    Robert L. Macdonald, M.D., Ph.D. Chair Department of Ne

PSEN1(M146V) Knock-In

RESEARCH MODELS These mice expresses PSEN1 with the M146V mutation associated with familial Alzheimer's disease. These mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. Homozygous mice produce only the mutant

PSEN1 Knock-out

RESEARCH MODELS These mice are deficient in PSEN1. This model is perinatal lethal in homozygouse animals which die shortly after birth presumably from breathing difficulties due to ribcage deformities (Shen et al., 1997). Gross skeletal malformations and central nervous

SAR228810

THERAPEUTICS Sanofi Immunotherapy (passive) APP and Amyloid-Related A multicenter Phase 1 trial testing six ascending doses of intravenous infusion and two doses of subcutaneous injection is testing safety, pharmacokinetics, and pharmacodynamics of SAR228810 in 48 pat

Octagam®

THERAPEUTICS Octapharma Intravenous Immunoglobulin NewGam Immunotherapy (passive) APP and Amyloid-Related Inflammation The first trial of this IVIG preparation in Alzheimer's evaluated six different doses of Octagam 10 percent against two placebo comparators in a

Gamunex

THERAPEUTICS Grifols Biologicals Inc. Intravenous Immunoglobulin Human Albumin Combined With Flebogamma Immunotherapy (passive) APP and Amyloid-Related Inflammation A multicenter Phase 2/3 trial being conducted in Spain is comparing three doses of 5 percent human albu

Ts65Dn

RESEARCH MODELS Modification Details Cesium irradiation produced a reciprocal translocation of chromosomes 16 and 17, creating a freely segregating, supernumerary chromosome Mmu1716 (1716). Summary This is a very well characterized model of Down syndrome that displays el

TetO-APPSweInd (line 102)

RESEARCH MODELS Modification Details Mouse APP695 with a humanized Aβ region and the Swedish (KM570/571NL) and Indiana (V617F) mutations downstream of a tetracycline-responsive promoter and mouse prion protein exons 1-2. Summary A tet-off system is used to overexpress a

TetO-APPSweInd (line 107)

RESEARCH MODELS Modification Details Mouse APP695 with a humanized Aβ region and the Swedish (KM570/571NL) and Indiana (V617F) mutations downstream of a tetracycline-responsive promoter and mouse prion protein exons 1-2. Summary A tet-off system is used to overexpress a

BIIB037

THERAPEUTICS Biogen Idec Immunotherapy (passive) APP and Amyloid-Related A Phase 1 safety and pharmacokinetics study began with a single ascending-dose trial of 0.3 mg/kg to 30 mg/kg intravenous BIIB037 in 56 people with mild to moderate AD. Participants were assessed

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE